Disclaimer – Forward Looking Statements

This presentation may include forward-looking statements. You can identify these statements by the fact that they use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” or similar expressions.

These forward looking statements speak only as at the date of this presentation and are based on management’s expectations and beliefs concerning future events. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of Avita Medical that could cause actual results to differ materially from such statements.

Avita Medical makes no undertaking to subsequently update or revise the forward-looking statements made in this release to reflect events or circumstances after the date of this release.

This presentation is intended to provide background information only and does not constitute or form part of an offer of securities or a solicitation or invitation to buy or apply for securities, nor may it or any part of it form the basis of, or be relied on in any connection with any contract or commitment whatsoever.
Overview of Avita Medical
AVITA Medical - Transforming Lives with Skin Regeneration

- Platform technology providing innovative treatments derived from the regenerative properties of a patient’s own skin
- Headquartered in California
- Traded on ASX, with ADRs in U.S.
- Substantial U.S. Government support under BARDA program

Leading the way in skin regenerative wound therapy
Acute thermal burns, trauma, & chronic wounds

Expanding our footprint within regenerative dermatology
Hypopigmentation: Vitiligo

Advancing into Cell and Cell-Based Gene Therapy
Aesthetics, Cell & Gene Therapy e.g., Dystrophic EB

FDA approved the RECELL System® PMA in September 2018 as Class III device for treatment of acute thermal burns
Leadership Team with the Right Expertise

Dr. Michael S. Perry  
CEO  
>30 years experience

Dale Sander  
CFO  
>30 years experience

Erin Liberto  
CCO  
16 years experience

Tim Rooney  
CAO  
25 years experience

Andrew Quick  
Sr VP, Clinical Dev.  
22 years experience

Donna Shiroma  
General Counsel  
20 years experience

Affiliations:
- NOVARTIS
- Schering-Plough
- BAY CITY CAPITAL
- Baxter
- PharSight
- SUTHERLAND
- Johnson & Johnson
- BIOLEX THERAPEUTICS
- Allergan
- dCI
- EcStrip
- AB
- sonova
- ASCEND THERAPEUTICS
- PDL BioPharm
- Ernst & Young
- SonaMed Corp
- Boston Scientific
- Johnson & Johnson
AVITA Medical Board and Capital Structure

**DIRECTORS**

- **Dr. Michael Perry**
  CEO, AVITA Medical

- **Lou Panaccio, Chairman**
  Non-Executive Director
  Sonic Healthcare Limited

- **Jeremy Curnock Cook**
  Managing Director of
  Bioscience Managers Pty Ltd

**Professor Suzanne Crowe**
Multiple positions including Associate Director of the Burnet Institute

**Louis Drapeau**
Nektar Therapeutics, BioMarin Pharmaceutical, Inc., and Arthur Andersen LLP.

**MAJOR SHAREHOLDERS**

- Karst Peak Capital Limited  15.6%
- Redmile Group  13.4%
- BioScience Managers Pty Ltd  5.1%

**ANALYSTS**

- John Hester, Bell Potter (AUS)
- Brooks O’Neil, Lake Street (US)

---

1. As of 7 March 2019
2. As of 31 December 2018, pro forma to include A$13.8 million and A$1.8 million in net proceeds received from 2nd Tranche of equity placement and Share Purchase Plan, respectively, in January 2019
RECELL Overview

Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL® Autologous Cell Harvesting Device for a full description of important safety information including contraindications, warnings and precautions.
RECELL System Skin Regeneration Platform

Regenerative Medicine Platform

- An Autologous Cell Harvesting Device that uses proprietary enzyme and buffer formulations to generate *Spray-on Skin™ Cells within 30 minutes*

**Designed by Surgeons**

- An elegant means to deliver skin regeneration to patients *at point of care*

**Proven Safety and Effectiveness**

- 8,000+ uses to date in multiple world markets with no observed safety signals
- Treatment area is 80X donor area (skin sample the size of credit card can be used to treat a patient’s entire back)
- Compelling clinical results (RCTs) and robust health-economic data

---

>50 Peer-Reviewed Publications
Current Standard of Care Is Suboptimal and Expensive

Autografts - Split-Thickness Skin Grafts (STSG) - Used in 75% of Cases

Harvesting skin from donor site for STSG

Donor site wound created while harvesting skin for autograft

Typical SOC donor site scar 52 weeks post procedure

KEY SHORTCOMINGS OF SOC

- Large donor area required
- Pain during and post procedure
- Extended hospitalization and costs
- Multiple complex, costly, surgical procedures
- Risk of infection

Healing burn injuries induces trauma of its own

Under Current Standard of Care
Average USD $792,000 cost and 59.4 days in hospital for 40% TBSA burns

U.S. Clinical Trials Supporting RECELL Use in Burns

Clinical Support for RECELL System

- Two multicenter, randomized, controlled clinical trials consisting of 131 patients
- Additional 155+ patients treated in Compassionate Use and Continued Access programs
- Real-world experience in more than 8,000 patients globally
Pivotal Trial 1: RECELL System Alone Versus SoC (STSG)
Deep-Partial Thickness (Second-Degree) Burns

- Significantly less donor-site pain ($p \leq 0.0025$)
- Significantly better donor-site appearance ($p \leq 0.0025$)
- Significantly reduced donor-site scarring ($p \leq 0.0025$)
- Significantly greater incidence of donor-site healing at two weeks ($p < 0.001$)

Equivalent healing of burn sites with significantly less donor skin required

Published in JBCR and Presented at ABA

Pivotal Trial 2: RECELL System Combined With Widely-Spaced Skin Grafts Versus SoC (STSG) Full-Thickness (Third-Degree) Burns

**Reduced Donor Skin Requirement**

- **Positive Treatment Outcome**
  - RECELL System achieved definitive closure comparable to standard of care with significantly less donor skin
  - At eight weeks post treatment,
    - **92 percent** of the burn sites treated with the RECELL System achieved complete healing versus
    - **85 percent** for the sites treated with the standard of care

![Graph showing reduced donor skin requirement compared to control](image)

"p<0.001"

32% reduction

Compassionate Use Provides Additional Case Studies

A CASE FROM A FACIAL BURN PATIENT
Case Series Presented at ABA Meeting - APRIL 2018

- 12-year-old girl with 2nd-degree facial burn and widespread 3rd-degree burns
- 62% Total Body Surface Area (TBSA) burn injury
- Insufficient donor skin available for SoC (STSG)
- Reintroduction of melanocytes resulted in an excellent cosmetic outcome
- No facial contracture release surgery required
- Discharged in 24 days

RECELL is ideal for treatment of facial burns
RECELL System Clinical Results: Over 50 Presentation in More than 20 Conferences During Past 12 Months

Presentations included:

- Pivotal studies in 2\textsuperscript{nd} and 3\textsuperscript{rd} burns
- Facial burn patients
- Health economic model demonstrating RECELL cost savings
- RECELL combined with dermal substitutes
- Reduction in hospital stay due to treatment with RECELL
- Necrotizing soft tissue infection
- Large TBSA burn injuries
Ten Presentations of RECELL System Results at American Burn Association Annual Meeting in April 2019

American Burn Association (ABA)
51st Annual Meeting
2-5 April 2019, Las Vegas

Treatment of Pediatric Patients with RECELL Selected at “Best of the Best Abstract”

Other presentations include:

- Developer, burn surgeon Professor Fiona Wood, to present a retrospective on the long-term clinical impact of the novel product
- Budget impact of RECELL use versus SOC (Arizona Burn Center)
- Treatment of donor sites with RECELL
- Large burn injuries, TBSA 52% to 91%
- Burn injuries of the hands and joints
Initial U.S. Target Market: In-Patient Burns of 10%+ TBSA that Require Autografting

486,000
Burn Patients
Treated Annually
in the US¹

42,402
In-patient
Burn Treatments²

75%
In-patient
Burns are Treated
in Burn Centers³

14,146
10%+ TBSA
In-Patients at
Burn Centers are
Target Candidates for RECELL⁴

---

² ABA NBR Annual Report 2017
³ Calculated off inpatient population and triangulated from http://ameriburn.org/who-we-are/media/burn-incidence-fact-sheet/ (accessed 02/08/2018)
2. Calculated from: http://ameriburn.org/who-we-are/media/burn-incidence-fact-sheet/
3. Calculated off inpatient population and triangulated from http://ameriburn.org/who-we-are/media/burn-incidence-fact-sheet/ (accessed 02/08/2018)
4. Through date of approval from clinical trials and Compassionate Use and Continued Access programs.
Health Economic Model Demonstrates RECELL Cost Savings Per-Patient Savings

- IQVIA (IMS) developed a Burn Care Pathway Health Economic model demonstrating RECELL savings
- Validated model provides VAC (Value & Analysis Committees) strong economic justification for adopting RECELL

**Figure 1: Relative cost per patient of current management versus RECELL by TBSA and depth**

**Conclusion:** Use of RECELL is expected to reduce costs across TBSA ranges for FT and DPT patients, with relative savings increasing as TBSA increases.

Use of the RECELL System could reduce the cost of treatment by 44% or greater in patients with large burns

Sets a New Standard of Validating Cost Effectiveness for Any New Product in Burns
Health Economic Model Demonstrates RECELL Cost Savings

Annual Burn Center Savings

- Model can be tailored to patient populations relevant to individual hospitals, healthcare systems, etc.
- Robust publication and podium schedule

**Conclusion:** Considering the expected mix of adult patients entering a typical burn center each year (as informed by NBR data), use of RECELL in burn management is expected to reduce costs overall.

For a burn center with 200 patients, the use of RECELL would reduce annual total treatment costs from $43.3 million to $30.3 million, saving 30% or $13.0 million

Customized Projections Can be Created for Each Burn Center Showing Annual Savings
RECELL System is Priced Right for All Burn Sizes
Pricing of Other Treatments Limit Them to Large Burns

Assumptions
• Skin TE $60/cm²
• Epicel ~$50/cm²; 1%TBSA treatment with Epicel costs at $6-10,000; Epicel Skin Grafts
• Integra $28/cm². Complementary product presented for pricing comparison
• RECELL® 1920 up to 10% TBSA. Complementary product presented for pricing comparison

RECELL is Priced for Broad Market Adoption

2. Sarah Schlatter, Biomedical Engineering, University of Rhode Island. Available at: http://www.ele.uri.edu/Courses/bme281/F08/Sarah_1.pdf
Creation of Best in Class Market Access Program Will Address Market Needs

Key Launch Need

Physician payment

Ensure Hospital Payment

Reimbursement Guidelines

Customers need quick, knowledgeable responses for reimbursement inquiries

Addressing the Need

CPT Codes

ICD-10 Code for procedural coding

Reimbursement and Coding Guides

Reimbursement Customer Service Line Director of Market Access

ABA Provided Recommended CPT Codes Within One Week of Approval

CPT = Current Procedural Terminology
ICD = Internal Classification of Disease
US Commercial Field Team is in Place

- **25** Average Years of Industry Experience (Sales Leadership)
- **15.8** Average Years of Burn Care Experience (Entire Field)
- **100%** Have Burn Care Experience
- **12** Average Years of Surgical Selling & Case Support Experience
- **100%** Have Successful Launched a New Product

20 Field Positions Will Provide Deep Coverage to All 134 US Burn Centers
All Preliminary Indicators Point to Success

Pre-Market Launch Scorecard

- FDA approval September 2018
- American Burn Association (ABA) issued reimbursement coding guidelines within one week of approval
- First commercial sale within two days of product availability
- A$1.1 million in U.S. sales for quarter ended 31 December 2018 without promotional effort
- Entire U.S. field force in place within eight weeks of approval

U.S. Sales Launch Commenced January 2019

- As of 28 February 2019:
  - 41 U.S. burn centers trained in use RECELL
  - 19 burn centers have ordered product
Pipeline and Milestones
# AVITA Medical Pipeline

## Development Programs

<table>
<thead>
<tr>
<th>Indication</th>
<th>Real-World Experience</th>
<th>POC Studies</th>
<th>Pivotal Trials</th>
<th>Approval U.S.</th>
<th>OUS¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thermal Burns Adults</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thermal Burns Pediatrics</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic Wounds: VLU and DFU</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypopigmentation: Vitiligo and Scars</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>Randomized controlled trials underway</td>
<td></td>
</tr>
<tr>
<td>Trauma Wounds</td>
<td>✓</td>
<td></td>
<td></td>
<td>Partner and take into pivotal trials</td>
<td></td>
</tr>
</tbody>
</table>

## Current RECELL Platform

- **OUS APPROVED INDICATIONS**
  - China: Burns, acute wounds, scars and vitiligo
  - Australia: Burns, acute wounds, scars and vitiligo
  - Japan: JPMDA application filed February 2019

## Cell and Gene Therapy

- Rejuvenation
- Skin diseases e.g. Epidermolysis

1. OUS APPROVED INDICATIONS
   - China: Burns, acute wounds, scars and vitiligo
   - Australia: Burns, acute wounds, scars and vitiligo
   - Japan: JPMDA application filed February 2019
Pediatric Opportunity

High Percentage of Burns are in Pediatric Patients
- 32% of burns occur between ages 5 and 15.9
- Majority suffer from scald burns (65%)

Avita has Initiated studies with RECELL in Pediatrics
- Q3 2018 - Commencement of US Paediatric Burns Clinical Trial
- Q3 2018 - Commencement of Australian Paediatric Scald Study

Scalds Allows Expansion into another Site-of-Service – Outpatient Setting

Case Study: 2-year old with Scald treated with RECELL

Before treatment

3 weeks post RECELL treatment

10 weeks post RECELL treatment

10 months post RECELL treatment
Financial Overview

<table>
<thead>
<tr>
<th>(AUD in 000s)</th>
<th>Six Months Ended December 31, 2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S. sales</td>
<td>$1,102</td>
<td>$-</td>
</tr>
<tr>
<td>Total revenue</td>
<td>6,822</td>
<td>4,465</td>
</tr>
<tr>
<td>Operating Costs</td>
<td>21,935</td>
<td>11,488</td>
</tr>
<tr>
<td>Net Loss</td>
<td>(14,205)</td>
<td>(7,306)</td>
</tr>
<tr>
<td>Cash</td>
<td>45,936(^1)</td>
<td>11,777</td>
</tr>
</tbody>
</table>

Tickers: ASX:AVH and OTCQX:AVMXY

BARDA Program

- U.S. Biomedical Advanced Research and Development Authority
  - Mandate: disaster preparedness & response
  - Providing sizable non-dilutive funding
  - Total estimated contract value US$80.1 million
- Major programs supported:
  - PMA
  - Health Economic Model
  - Pediatric clinical trials
  - Disaster preparedness stockpile

\(^1\)As of 31 December 2018, pro forma to include A$13.8 million and A$1.8 million in net proceeds received from 2nd Tranche of equity placement and Share Purchase Plan, respectively, in January 2019
2018/2019 Value-Creating Milestones

• **2018 was a Transformative Year for AVITA**
  - PMA approval by U.S. Food & Drug Administration
  - High impact of RECELL clinical data
  - Accelerated launch preparation activities
  - Development of robust manufacturing capabilities
  - Pipeline advancement

• **RECELL is Positioned for Successful Adoption in US Burns during 2019**

• **Key milestones for 2019**
  - RECELL U.S. market launch / revenue growth
  - Publication of RECELL health economic model
  - Ten presentations of RECELL results at 2019 ABA meeting
  - Commencement of traumatic wounds pivotal clinical trial
  - Commencement of vitiligo clinical trial(s)
  - BARDA procurement
  - Listing of ADRs on NASDAQ
Risk Factors

There are numerous risk factors involved with the Company’s business. Some of these risks can be mitigated by the use of safeguards and appropriate systems and controls, but some are outside the control of the Company and cannot be mitigated. Accordingly, an investment in the Company carries no guarantee with respect to the payment of dividends, return of capital or price at which securities will trade. The following is a summary of the more material matters to be considered. However, this summary is not exhaustive. Potential investor should consult their professional advisors before deciding whether to invest.

- **Technological Change**: Technological change presents the Company with significant opportunities for growth. However, the risk remains that any competitor may introduce new technology enabling it to gain a significant competitive advantage over the Company.

- **Reliance on key personnel**: The Company's success depends to a significant extent upon its key management personnel, as well as other management and technical personnel including sub-contractors. The loss of the services of any such personnel could have an adverse effect on the Company.

- **Competition**: The Company competes with other companies, including nationally in Australia and internationally. Some of these companies have greater financial and other resources than the Company and, as a result, may be in a better position to compete for future business opportunities. There can be no assurance that the Company can compete effectively with these companies.

- **Patent Protection**: The patent protection that the Company may obtain varies from product to product and country to country and may not be sufficient, including to maintain product exclusivity. Patent rights are also limited in time and do not always provide effective protection for products and services: competitors may successfully avoid patents through design innovation, the Company may not hold sufficient evidence of infringement to bring suit, or the infringement claim may not result in a decision that the rights are valid, enforceable or infringed. Legislation or regulatory actions subsequent to the filing date of a patent application may affect what an applicant is entitled to claim in a pending application and may also affect whether a granted patent can be enforced in certain circumstances. Laws relating to biotechnology remain the subject of ongoing political controversy in some countries. The risk of changed laws affecting patent rights is generally considered greater for the biotechnology field than in other longer established fields.

- **Change in government policy and legislation**: Any material adverse changes in relevant government policies or legislation of Australia / United States may affect the viability and profitability of the Company, and consequent returns to investors. The activities of the Company are subject to various federal, state and local laws governing prospecting, development, production, taxes, labor standards and occupational health and safety, and other matters."
Appendix
Mechanism and Additional Burn Case Studies
ReCell processes small samples of patients’ own skin to create a cell suspension of disaggregated cells. Disaggregated skin cells in suspension form new tissue across the entire area rather than waiting for cellular resources from the wound edge.

- Cell suspension includes pigment-producing cells (melanocytes)
- Cell suspension facilitates re-epithelialization of areas of viable dermis (partial-thickness burns), and areas within the spaces of split-thickness autografts for full-thickness burns
RECELL Achieved Healing and Pigmentation When Standard of Care Failed

Case Report: RECELL Treatment Outcome for Deep Partial-Thickness Burn

- 48-year-old victim of a gas boiler explosion
- Standard of care failed to heal the 2nd degree facial burn wounds
- Use of RECELL achieved wound healing
- Reintroduction of melanocytes resulted in an excellent cosmetic outcome
- RECELL’s unique advantages make it the ideal solution for facial burns and other visible burn sites

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Post-Operation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excision and ReCell®</td>
<td>14 weeks</td>
</tr>
</tbody>
</table>

Restoration of Normal Pigment Critical For Patients
Appendix

Follow-On Indications Beyond Burns
RECELL Presents a Strategic Opportunity in Traumatic Wounds

<table>
<thead>
<tr>
<th>Wound Type</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Degloving</td>
<td>68%</td>
</tr>
<tr>
<td>Crush Wounds</td>
<td>61%</td>
</tr>
<tr>
<td>Gunshot Wounds</td>
<td>56%</td>
</tr>
<tr>
<td>Lacerations</td>
<td>50%</td>
</tr>
<tr>
<td>Pretibial Lacerations</td>
<td>28%</td>
</tr>
<tr>
<td>Abrasions</td>
<td>21%</td>
</tr>
</tbody>
</table>

- ~1/3 of all skin grafts are trauma related
- ~50% of Burn Surgeons also work in trauma centers
  - Synergistic with current commercial efforts in burns
- RECELL used by multiple international surgeons in Traumatic Wounds with positive outcomes

1. 2018 Internal Market Research
2. 2018 IMS Data
3. US Skin Graft Market – Industry Trends Forecast to 2025
Regenerative Dermatology Opportunity in Vitiligo

High Market Value • Large Population • Focused to a Specialty • Clinical Data

$2B Global Market¹

>10M (US & China)²,³

Extremely low patient & doctor satisfaction with existing products⁴

5 RECELL & Vitiligo publications with positive outcomes

---

¹. Research & Markets: Vitiligo Therapeutics - Pipeline Assessment and Market Forecasts to 2019 2012
³. The Epidemiology and Treatment of Vitiligo: A Chinese Perspective Xiaolan Ding, Juan Du and Jianzhong Zhang* Journal of Pigmentary Disorders. 2014
⁴. Internal market research 2018
RECELL Was Able to Repigment 100% at 6-months (Vitiligo)

- After 6-months, the RECELL-treated area is 100% re-pigmented, with mild hyperpigmentation (UVA daily)
- Control area is 0% re-pigmented
### Early Research Programs to Advance RECELL Platform

**High Market Value ● Focused to a Specialty ● Expansion into other Disease States**

<table>
<thead>
<tr>
<th>Cell-based Skin Gene Therapy</th>
<th>Skin Aesthetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>e.g., Epidermolysis Bullosa (EB)</td>
<td>$22B Global Market&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

**EB**: An incurable, group of genetic disorders characterized by skin fragility and blistering

- 25-50K/yr (US)<sup>1</sup>

- >1MM aesthetic procedures/yr (US)<sup>2</sup>

**Evolution of current RECELL platform required to incorporate cellular manipulation and/or genetically modified cells**

**Successful development of engineered (autologous) cell therapies will create a pathway to other applications**

---

1. National Epidermolysis Bullosa Registry
2. 2017 Plastic Surgery Statistics Report